Graft-Versus-Host Disease

High-dose oral vitamin A prior to hematopoietic stem cell transplantation reduced the incidence of graft-versus-host disease with minimal toxicity, according to study data published in Blood.

The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

The microbiome is linked to myriad processes in human health and disease.

The FDA announced several regulatory actions.

A phase 2 trial of axatilimab for chronic graft-versus-host disease met its primary endpoint, according to the agent’s manufacturer.

Chronic graft-versus-host disease is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation.

For years now, transplant physicians have spoken different languages when referring to a matter of utmost relevance — graft-versus-host disease.

A treosulfan-based reduced-toxicity conditioning regimen has significantly improved hematopoietic cell transplantation outcomes for patients with high-risk thalassemia major and hematologic malignancies.

Chronic graft-versus-host disease continues to be a leading cause of late morbidity and mortality, complicating approximately 35% to 50% of allogeneic transplantations.

A short course of itacitinib induced high response rates among patients with low-risk acute graft-versus-host disease, according to study results.